HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CF PHARMTECH

14.090

-0.420-2.89%

Volume:2.21M

Turnover:30.61M

Market Cap:6.09B

PE:2.13K

High:14.630

Open:14.630

Low:13.360

Close:14.510

52wk High:48.800

52wk Low:13.360

Shares:432.00M

HK Float Shares:323.00M

Volume Ratio:0.37

T/O Rate:0.68%

Dividend:- -

Dividend Rate:- -

EPS(LYR):0.007

ROE:0.21%

ROA:-0.83%

PB:3.55

PE(LYR):2,134.85

PS:12.06

Loading ...

Overview Company News Filings

CF PharmTech Monthly Return: 551,000 H-Share Repurchase Pushes Treasury Stock to 1.22 Million

Bulletin Express

CF PharmTech Sets 26 June AGM to Approve 2025 Results, Board Refresh, H-Share Incentive Expansion and Dual Capital Mandates

Bulletin Express

CF PHARMTECH (02652) Announces NMPA Approval for ICF004 Investigational New Drug Application

CF Pharmtech - Nmpa Approves Ind Application for ICF004 as Class 1 New Drug

THOMSON REUTERS

CF PharmTech Updates Board Structure and Committee Line-up

Bulletin Express

CF PHARMTECH (02652) Announces Proposed Nomination of Zhang Jingjing as Executive Director

CF Pharmtech files directors list with Hong Kong Stock Exchange

CF PharmTech non-executive director Chen Penghui resigns effective May 29, 2026

CF Pharmtech Inc - to Nominate Zhang Jingjing as Candidate for Executive Director

THOMSON REUTERS

CF PharmTech Repurchases 64,500 H Shares for HKD 1.29 Million, Lifts Treasury Stock to 1.17 Million

Bulletin Express

CF PHARMTECH (02652) Executed HK$1.29 Million Share Buyback on May 28

CF PharmTech Files Southeast Asia Marketing Authorization Application for Inhalation Drug; Shares Up 4%

MT Newswires Live

CF PHARMTECH (02652): CF017 Submits Marketing Authorization Application in Southeast Asia

CF PharmTech files for Southeast Asian approval of inhaled budesonide CF017, advancing global commercialization strategy

Bulletin Express

CF PharmTech submits CF017 inhalation drug marketing application in Southeast Asia

CF PHARMTECH (02652) Invests HK$1.3544 Million in Share Buyback on May 26

CF PharmTech repurchases 67,500 H-shares at HK$20.06 average; outstanding shares trimmed to 301.16 million

Bulletin Express

CF PharmTech's Bronchospasm Secures China Marketing Approval

MT Newswires Live

CF PHARMTECH (02652) Announces NMPA Acceptance of Tiotropium Bromide Powder for Inhalation Marketing Application

CF PharmTech says NMPA accepts marketing application for tiotropium bromide inhalation powder

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/02652/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02652","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","market":"HK","secType":"STK","nameCN":"CF PHARMTECH","latestPrice":14.09,"timestamp":1788163728003,"preClose":14.51,"halted":0,"volume":2206300,"delay":0,"changeRate":-0.028945554789800133,"floatShares":323000000,"shares":432000000,"eps":0.0066,"marketStatus":"Not Yet Opened","change":-0.42,"latestTime":"08-31 16:08:48","open":14.63,"high":14.63,"low":13.36,"amount":30613179,"amplitude":0.087526,"askPrice":14.1,"askSize":1000,"bidPrice":14.09,"bidSize":500,"shortable":3,"etf":0,"ttmEps":0.006,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1759852800000,"exchange":"SEHK","adjPreClose":14.51,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.3694766069085516,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","floatShares":323000000,"roa":"-0.83%","roe":"0.21%","lyrEps":0.0066,"volumeRatio":0.3694766069085516,"shares":432000000,"dividePrice":0,"high":14.63,"amplitude":0.087526,"preClose":14.51,"low":13.36,"week52Low":13.36,"pbRate":"3.55","psRate":"12.06","week52High":48.8,"institutionHeld":0,"latestPrice":14.09,"committee":-0.333333,"eps":0.0066,"divideRate":0,"volume":2206300,"delay":0,"ttmEps":0.006,"open":14.63,"prevYearClose":35,"prevWeekClose":14.51,"prevMonthClose":14.09,"prevQuarterClose":21,"fiveDayClose":15.21,"twentyDayClose":17.04,"sixtyDayClose":20.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02652\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"02652","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-30","symbol":"02652","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02652\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02652\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02652\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02652","date":"2026-08-28","current":2348.333333,"percent":0.543779,"low":-293.764894,"twenty":420.751477,"median":499.411825,"eighty":2817.123583,"high":3595.964728,"avg":1488.786136,"sd":1184.163366,"marketCap":5957535925},"quantilePoints":[{"date":"2025-10-10","current":420.512992,"twenty":-8.053739,"median":420.512992,"eighty":438.465035,"marketCap":12738371726},{"date":"2025-10-17","current":400.969089,"twenty":380.917252,"median":393.18793,"eighty":412.695431,"marketCap":12136883281},{"date":"2025-10-24","current":382.04749,"twenty":383.954109,"median":395.798507,"eighty":407.879105,"marketCap":11568353106},{"date":"2025-10-31","current":411.638127,"twenty":385.87135,"median":395.798507,"eighty":410.009732,"marketCap":12482945126},{"date":"2025-11-07","current":380.629431,"twenty":385.87135,"median":397.412529,"eighty":410.009732,"marketCap":11535394836},{"date":"2025-11-14","current":413.442652,"twenty":386.82146,"median":399.24986,"eighty":411.625005,"marketCap":12565340803},{"date":"2025-11-21","current":474.663516,"twenty":387.596392,"median":401.654037,"eighty":419.1227,"marketCap":14419243545},{"date":"2025-11-28","current":513.213561,"twenty":390.697015,"median":408.734506,"eighty":451.19497,"marketCap":15646939138},{"date":"2025-12-05","current":509.365027,"twenty":391.797785,"median":411.605323,"eighty":487.699676,"marketCap":15556303893},{"date":"2025-12-12","current":478.26383,"twenty":394.588712,"median":413.442652,"eighty":485.541496,"marketCap":14633472306},{"date":"2025-12-19","current":468.273561,"twenty":396.041553,"median":429.606948,"eighty":482.974301,"marketCap":14361566570},{"date":"2025-12-24","current":469.497744,"twenty":396.770692,"median":439.211078,"eighty":482.563912,"marketCap":14443962248},{"date":"2026-01-02","current":452.984556,"twenty":397.492287,"median":451.385447,"eighty":481.570975,"marketCap":13990786022},{"date":"2026-01-09","current":417.797013,"twenty":398.674444,"median":438.955991,"eighty":480.057858,"marketCap":12936121351},{"date":"2026-01-16","current":442.060347,"twenty":399.985866,"median":432.778937,"eighty":478.730146,"marketCap":13731858722},{"date":"2026-01-23","current":466.639698,"twenty":400.772068,"median":439.902936,"eighty":477.371374,"marketCap":14481468286},{"date":"2026-01-30","current":480.840623,"twenty":401.791027,"median":446.916666,"eighty":477.757159,"marketCap":14990389486},{"date":"2026-02-06","current":464.022312,"twenty":403.190746,"median":452.185001,"eighty":477.033593,"marketCap":14502764350},{"date":"2026-02-13","current":452.173894,"twenty":406.744138,"median":454.320794,"eighty":475.6532,"marketCap":14213623359},{"date":"2026-02-20","current":472.094804,"twenty":408.734506,"median":454.916554,"eighty":476.776403,"marketCap":14818441932},{"date":"2026-02-27","current":505.751529,"twenty":411.273773,"median":459.838493,"eighty":479.42962,"marketCap":16048983093},{"date":"2026-03-06","current":445.246344,"twenty":411.572519,"median":460.887466,"eighty":481.94993,"marketCap":14015073071},{"date":"2026-03-13","current":299.287031,"twenty":402.338985,"median":457.528006,"eighty":481.000215,"marketCap":9464083401},{"date":"2026-03-20","current":315.053976,"twenty":397.81132,"median":454.320794,"eighty":480.840623,"marketCap":9924943114},{"date":"2026-03-27","current":299.095644,"twenty":391.175665,"median":451.779671,"eighty":479.42962,"marketCap":9398246299},{"date":"2026-04-02","current":3318.248683,"twenty":389.832113,"median":451.779671,"eighty":480.872541,"marketCap":9381570423},{"date":"2026-04-10","current":3321.445916,"twenty":390.816678,"median":452.984556,"eighty":482.236241,"marketCap":9463036901},{"date":"2026-04-17","current":3317.060015,"twenty":392.419904,"median":455.282385,"eighty":483.410603,"marketCap":9454509433},{"date":"2026-04-24","current":2996.4431,"twenty":394.891161,"median":460.26919,"eighty":490.336167,"marketCap":8541149514},{"date":"2026-04-30","current":3202.871531,"twenty":396.041553,"median":462.144769,"eighty":499.979081,"marketCap":9131900891},{"date":"2026-05-08","current":3148.404437,"twenty":397.173254,"median":463.774025,"eighty":508.169798,"marketCap":9007763175},{"date":"2026-05-15","current":2973.181714,"twenty":398.099028,"median":464.50673,"eighty":512.854422,"marketCap":8528814526},{"date":"2026-05-22","current":2811.882705,"twenty":399.495195,"median":466.720409,"eighty":2921.871357,"marketCap":8047680823},{"date":"2026-05-29","current":3180.044455,"twenty":400.476536,"median":467.247998,"eighty":2926.706614,"marketCap":9133017429},{"date":"2026-06-05","current":2895.334441,"twenty":400.969089,"median":468.273561,"eighty":2926.706614,"marketCap":8327404730},{"date":"2026-06-12","current":2591.262092,"twenty":402.338985,"median":469.314298,"eighty":2919.612019,"marketCap":7447807192},{"date":"2026-06-18","current":2679.987141,"twenty":403.474666,"median":471.144686,"eighty":2910.923271,"marketCap":7719084937},{"date":"2026-06-26","current":2653.65777,"twenty":407.739322,"median":472.774581,"eighty":2903.774482,"marketCap":7608107678},{"date":"2026-07-03","current":2674.595079,"twenty":410.258066,"median":474.904398,"eighty":2905.018632,"marketCap":7673871980},{"date":"2026-07-10","current":2510.065653,"twenty":411.453021,"median":477.841604,"eighty":2898.212797,"marketCap":7192970522},{"date":"2026-07-17","current":2212.458756,"twenty":411.611884,"median":479.42962,"eighty":2892.703479,"marketCap":6362696210},{"date":"2026-07-24","current":2249.530522,"twenty":411.787912,"median":481.475073,"eighty":2888.435745,"marketCap":6470762659},{"date":"2026-07-31","current":2830.800739,"twenty":412.509722,"median":482.52515,"eighty":2884.270453,"marketCap":8158252159},{"date":"2026-08-07","current":2582.169982,"twenty":413.490204,"median":483.399827,"eighty":2872.355071,"marketCap":7456157987},{"date":"2026-08-14","current":2399.972298,"twenty":415.255724,"median":487.118208,"eighty":2848.370255,"marketCap":6938825440},{"date":"2026-08-21","current":2153.795127,"twenty":418.883405,"median":491.347467,"eighty":2826.107192,"marketCap":6240837082},{"date":"2026-08-28","current":2055.558094,"twenty":420.751477,"median":499.411825,"eighty":2817.123583,"marketCap":5957535925}],"updateTime":1788197410353},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02652\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1149956112","title":"CF PharmTech Monthly Return: 551,000 H-Share Repurchase Pushes Treasury Stock to 1.22 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1149956112","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149956112?lang=en_us&edition=fundamental","pubTime":"2026-06-03 17:05","pubTimestamp":1780477545,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. submitted its Monthly Return for the period ended 31 May 2026 to Hong Kong Exchanges and Clearing Limited on 03 June 2026. • Registered capital remained unchanged at 411.98 million...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174360035","title":"CF PharmTech Sets 26 June AGM to Approve 2025 Results, Board Refresh, H-Share Incentive Expansion and Dual Capital Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1174360035","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174360035?lang=en_us&edition=fundamental","pubTime":"2026-06-02 23:03","pubTimestamp":1780412602,"startTime":"0","endTime":"0","summary":"CF PharmTech will convene its annual general meeting (AGM) on 26 June 2026 in Suzhou to seek shareholder approval on nine key resolutions that shape its next operating cycle and capital strategy. Key...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122546310","title":"CF PHARMTECH (02652) Announces NMPA Approval for ICF004 Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1122546310","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122546310?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:10","pubTimestamp":1780272631,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) has announced that the Investigational New Drug (IND) application for ICF004 inhalation powder, a Class I new drug, has recently been approved by China's National Medical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989785","title":"CF Pharmtech - Nmpa Approves Ind Application for ICF004 as Class 1 New Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989785?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:00","pubTimestamp":1780272038,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nFWN42800I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175962402","title":"CF PharmTech Updates Board Structure and Committee Line-up","url":"https://stock-news.laohu8.com/highlight/detail?id=1175962402","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175962402?lang=en_us&edition=fundamental","pubTime":"2026-05-29 22:23","pubTimestamp":1780064609,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. released an announcement on 29 May 2026 detailing the latest composition of its Board of Directors and the three principal Board committees. The Board now comprises ten members....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159833172","title":"CF PHARMTECH (02652) Announces Proposed Nomination of Zhang Jingjing as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1159833172","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159833172?lang=en_us&edition=fundamental","pubTime":"2026-05-29 22:20","pubTimestamp":1780064419,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) has announced that Mr. Chen Penghui has resigned from his position as a non-executive director, effective May 29, 2026, due to his desire to dedicate more time to other...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639673617","title":"CF Pharmtech files directors list with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2639673617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639673617?lang=en_us&edition=fundamental","pubTime":"2026-05-29 22:13","pubTimestamp":1780064009,"startTime":"0","endTime":"0","summary":"CF Pharmtech filed an updated board list with the Hong Kong Stock Exchange dated May 29, 2026.Bill Wenqing Liang remains chairperson of the board, serving as an executive director.The board comprises four executive directors, two non-executive directors, four independent non-executive directors.Audit Committee chaired by independent non-executive director Lijuan Wang; members include Jian Jin, Wang Hoi Ip.Remuneration and Appraisal Committee chaired by independent non-executive director Wang Hoi Ip; Nomination Committee chaired by independent non-executive director Shirong Wei.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the regulatory disclos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLcyr6L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639067356","title":"CF PharmTech non-executive director Chen Penghui resigns effective May 29, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2639067356","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639067356?lang=en_us&edition=fundamental","pubTime":"2026-05-29 22:09","pubTimestamp":1780063773,"startTime":"0","endTime":"0","summary":"CF PharmTech disclosed board and supervisory committee changes dated May 29, 2026.Non-executive director Chen Penghui resigned, effective May 29, 2026, citing other professional commitments.Supervisor and supervisory committee chair Zhang Jingjing resigned effective May 29, 2026, tied to her nomination as an executive director.Zhang, 38, has led the supervisory committee since 2021 and holds group HR and marketing management roles, including assistant general manager.Yao Zheng, 38, a capital markets and investment professional, was nominated as supervisor and supervisory committee chair; he currently chairs a private fund manager.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to ge","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL87lXpc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639673347","title":"CF Pharmtech Inc -  to Nominate Zhang Jingjing as Candidate for Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2639673347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639673347?lang=en_us&edition=fundamental","pubTime":"2026-05-29 22:09","pubTimestamp":1780063766,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nFWN4260U8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196857986","title":"CF PharmTech Repurchases 64,500 H Shares for HKD 1.29 Million, Lifts Treasury Stock to 1.17 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1196857986","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196857986?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:23","pubTimestamp":1779971012,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. (HKEX: 02652) has filed a Next Day Disclosure Return detailing the on-market repurchase of 64,500 H shares on 28 May 2026. Key points are as follows: • Transaction details: Shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172004583","title":"CF PHARMTECH (02652) Executed HK$1.29 Million Share Buyback on May 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1172004583","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172004583?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:20","pubTimestamp":1779970828,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that on May 28, 2026, the company repurchased 64,500 of its shares at a total cost of approximately HK$1.29 million.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638806655","title":"CF PharmTech Files Southeast Asia Marketing Authorization Application for Inhalation Drug; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638806655","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638806655?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:03","pubTimestamp":1779933792,"startTime":"0","endTime":"0","summary":"CF PharmTech  submitted a marketing authorization application for CF017, a budesonide suspension for inhalation, in a Southeast Asian market, according to a Thursday Hong Kong bourse filing.The drug was approved in China in 2021 and has since been commercialized in the mainland, the filing said.Shares of the company rose nearly 4% in morning trade Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CF","BK1191","BK4093","02652","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122715217","title":"CF PHARMTECH (02652): CF017 Submits Marketing Authorization Application in Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=1122715217","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122715217?lang=en_us&edition=fundamental","pubTime":"2026-05-28 08:07","pubTimestamp":1779926856,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that the group has recently submitted a marketing authorization application for CF017 (Budesonide Suspension for Inhalation) to relevant drug regulatory authorities in...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","IPOS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127781086","title":"CF PharmTech files for Southeast Asian approval of inhaled budesonide CF017, advancing global commercialization strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1127781086","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127781086?lang=en_us&edition=fundamental","pubTime":"2026-05-28 08:03","pubTimestamp":1779926595,"startTime":"0","endTime":"0","summary":"CF PharmTech (Stock Code: 02652) announced the submission of a marketing authorization application for CF017, a budesonide suspension for inhalation, to the drug regulatory authority of an unnamed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638378706","title":"CF PharmTech submits CF017 inhalation drug marketing application in Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2638378706","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638378706?lang=en_us&edition=fundamental","pubTime":"2026-05-28 08:01","pubTimestamp":1779926469,"startTime":"0","endTime":"0","summary":"CF PharmTech submitted a marketing authorization application for CF017, a budesonide inhalation suspension, to a Southeast Asian drug regulator.CF017 won China approval in May 2021; the filing signals a push to expand commercialization outside China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLbqb9rz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146531325","title":"CF PHARMTECH (02652) Invests HK$1.3544 Million in Share Buyback on May 26","url":"https://stock-news.laohu8.com/highlight/detail?id=1146531325","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146531325?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:24","pubTimestamp":1779798254,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) announced that on May 26, 2026, the company executed a share repurchase, spending HK$1.3544 million to acquire 67,500 shares at a price range of HK$18.90 to HK$20.38 per share.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185729830","title":"CF PharmTech repurchases 67,500 H-shares at HK$20.06 average; outstanding shares trimmed to 301.16 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1185729830","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185729830?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:23","pubTimestamp":1779798197,"startTime":"0","endTime":"0","summary":"CF PharmTech, Inc. disclosed a share buy-back on 26 May 2026, acquiring 67,500 H-shares on the Hong Kong Stock Exchange. The repurchase was executed within a price range of HK$18.90 to HK$20.38 per...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638093564","title":"CF PharmTech's Bronchospasm Secures China Marketing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2638093564","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638093564?lang=en_us&edition=fundamental","pubTime":"2026-05-26 10:46","pubTimestamp":1779763615,"startTime":"0","endTime":"0","summary":"CF PharmTech  said Chinese regulators had accepted its marketing authorization application for tiotropium bromide inhalation powder for review, according to a Tuesday filing with the Hong Kong bourse.The product is designed to treat bronchospasm associated with chronic obstructive pulmonary disease and help keep reduce exacerbations associated with the condition.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4093","BK4585","BK4588","CF","BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157418315","title":"CF PHARMTECH (02652) Announces NMPA Acceptance of Tiotropium Bromide Powder for Inhalation Marketing Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1157418315","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157418315?lang=en_us&edition=fundamental","pubTime":"2026-05-26 08:14","pubTimestamp":1779754459,"startTime":"0","endTime":"0","summary":"CF PHARMTECH (02652) has announced that the marketing authorization application for its Tiotropium Bromide Powder for Inhalation product has been accepted by the National Medical Products...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638563787","title":"CF PharmTech says NMPA accepts marketing application for tiotropium bromide inhalation powder","url":"https://stock-news.laohu8.com/highlight/detail?id=2638563787","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638563787?lang=en_us&edition=fundamental","pubTime":"2026-05-26 08:01","pubTimestamp":1779753677,"startTime":"0","endTime":"0","summary":"CF PharmTech’s marketing authorization application for tiotropium bromide inhalation powder was accepted for review by China’s NMPA.The product targets COPD bronchospasm treatment, including reducing exacerbations.The filing acceptance does not grant marketing approval; the application remains subject to further regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL3tXRWC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":150,"code":"91000000","status":"200"}]}}